Opus Genetics, Inc. last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $755,000 (-73.8% year over year) and diluted EPS of -$0.14. It usually reports 37–50 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 11, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 12, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–50 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-73.8%
|
-8
-9.1%
|
-0.14
-16.7%
|
|
May 12, 2026
42 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2
-50.6%
|
-66
-699.8%
|
-0.75
-212.5%
|
|
Feb 19, 2026
50 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
4
-10.2%
|
-17
+53.0%
|
-0.21
+82.2%
|
|
Nov 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3
-20.4%
|
-17
-131.9%
|
-0.25
+13.8%
|
|
Aug 13, 2025
44 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
3
+159.2%
|
-7
+4.4%
|
-0.12
+60.0%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
4
+155.4%
|
-8
-15.3%
|
-0.24
+17.2%
|
|
Oct 22, 2024
22 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
4
-67.6%
|
-8
-235.3%
|
-0.29
-216.0%
|
|
Aug 13, 2024
44 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IRD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1228627
- Former names
- Ocuphire Pharma, Inc. (until Oct 22, 2024); REXAHN PHARMACEUTICALS, INC. (until Nov 9, 2020); CORPORATE ROAD SHOW DOT COM INC (until Apr 29, 2005); FERRARO FRANK (until Apr 29, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.